Does Humana Cover Metformin? A Woman's Complete Guide to Coverage, Costs, and Life-Stage Considerations

Does Humana Actually Cover Metformin?

Yes. Metformin is one of the most consistently covered drugs on Humana formularies across all plan types. As a first-line agent for type 2 diabetes management, metformin appears on Humana's Medicare Part D, HMO, and PPO drug lists, usually at the lowest cost-sharing tier available. For most women, this means paying between $0 and $10 for a 30-day supply of the generic immediate-release tablets.

Generic metformin hydrochloride has been available since the early 2000s, and its price has fallen sharply. The real coverage question is not whether Humana covers it at all. The question is which formulation, which dose, and for which diagnosis you are filling it.

How Humana Organizes Drug Tiers

Humana uses a multi-tier formulary system where Tier 1 is typically preferred generics with the lowest copay, Tier 2 is non-preferred generics or certain low-cost brand drugs, and higher tiers carry progressively higher cost-sharing. Metformin immediate-release consistently lands at Tier 1 on most Humana plans.

Immediate-Release vs. Extended-Release: Does the Distinction Matter for Coverage?

Immediate-release metformin (500 mg, 850 mg, 1,000 mg tablets) is almost universally covered at Tier 1. Extended-release metformin (metformin ER, sometimes branded as Glucophage XR or Fortamet) may sit at Tier 2 or higher, and some Humana plans require step therapy, meaning you must try and document a reason to move away from IR before ER is approved at the lower cost-share rate.

For women who switch to ER specifically to reduce GI side effects (a common reason women request it, since nausea is reported more frequently in female patients at initiation), a prior authorization request from your prescriber citing GI intolerance of IR is usually sufficient to get ER approved at the preferred tier.

Which Humana Plans Cover Metformin?

Medicare Advantage and Part D Plans

Humana operates one of the largest Medicare Part D networks in the country. Medicare Part D plans are required by CMS to cover at least two drugs in each therapeutic class, and metformin, as the anchor biguanide for type 2 diabetes, is on every Humana Part D formulary. Women 65 and older with type 2 diabetes or prediabetes filling metformin through a Humana Medicare Advantage prescription drug (MAPD) plan should expect a $0 to $5 Tier 1 copay.

Commercial HMO and PPO Plans (Employer-Sponsored or Individual Market)

Humana's commercial plans, including those sold on state and federal ACA marketplaces, also include metformin at Tier 1 or Tier 2. The Affordable Care Act requires most commercial plans to cover preventive medications at no cost when prescribed for a USPSTF A- or B-rated indication. Metformin for prediabetes prevention falls under USPSTF guidance, meaning some commercial Humana plans may cover it at $0 for qualifying patients even before deductible.

Humana Medicaid Plans

Where Humana operates Medicaid managed care (in states such as Kentucky, Florida, and Ohio), metformin is covered as a preferred drug on state preferred drug lists. Medicaid cost-sharing is minimal, often $1 to $3 per fill.

How to Check Your Specific Humana Plan's Metformin Coverage

Coverage tiers shift every January 1 when plan formularies are updated. The most reliable steps:

1. Log in to MyHumana at humana.com and use the Drug Cost & Coverage tool. Enter "metformin" and your dosage.
2. Call the Humana pharmacy benefits number on the back of your insurance card and ask specifically: "What tier is metformin immediate-release 500 mg, and is the extended-release formulation covered at the same tier?"
3. Ask your pharmacist to run a test claim before you fill. This shows your exact out-of-pocket cost with your current plan.
4. If your prescriber is writing metformin for an off-label indication (PCOS, longevity, weight management), ask them which ICD-10 code they are submitting, because insurance coverage of off-label metformin depends heavily on the diagnosis code.

Women-Specific Uses of Metformin: How Coverage Applies Across Life Stages

This is where most insurance articles fail women. Metformin is not just a diabetes drug. Its uses in women span the entire reproductive lifespan and beyond, and insurance coverage is not identical across all indications.

Reproductive Years: PCOS and Fertility

Polycystic ovary syndrome (PCOS) affects an estimated 8 to 13 percent of reproductive-age women worldwide, making it one of the most common reasons a woman in her 20s or 30s fills metformin. Metformin improves insulin sensitivity and can restore menstrual regularity in women with PCOS, even when diabetes is not present.

Here is the coverage gap: metformin prescribed with a PCOS diagnosis code (ICD-10 E28.2) may be covered, denied, or covered at a different tier than the same drug prescribed for type 2 diabetes, depending on your specific Humana plan. Some commercial plans treat it as a covered diabetic agent regardless of indication. Others require documentation that the patient has insulin resistance before approving coverage. Your prescriber can submit a letter of medical necessity if an initial claim is denied.

The American Society for Reproductive Medicine (ASRM) Practice Committee recommends metformin as a treatment option for ovulation induction and metabolic management in women with PCOS, which gives prescribers a strong clinical basis for that letter.

Trying to Conceive and Early Pregnancy

This section is required reading if you are trying to conceive while taking metformin. Metformin crosses the placenta. Human data, including the MiG trial, show that metformin is detectable in fetal circulation at concentrations similar to maternal levels. For gestational diabetes management, some clinicians use metformin, but the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 190 notes that while metformin may be used for gestational diabetes in patients who decline or cannot tolerate insulin, insulin remains the preferred agent because long-term neonatal outcomes with metformin exposure are still under study.

From a coverage standpoint, Humana will generally cover metformin during pregnancy if the submitted diagnosis is gestational diabetes (ICD-10 O24.4) or pre-existing type 2 diabetes in pregnancy, because it is a covered formulary drug regardless of pregnancy status. The decision to continue or stop is clinical, not a coverage issue.

Contraception note. Metformin is not a teratogen in the classical sense, and it does not require contraception the way thalidomide or isotretinoin do. Women with PCOS who resume ovulation on metformin and do not want to conceive should use contraception, because restored ovulation is a treatment success, not a side effect to ignore.

Postpartum and Lactation

Metformin is present in breast milk. A pharmacokinetic study published in Diabetes Care measured metformin concentration in breast milk and found the relative infant dose to be approximately 0.28 percent of the weight-adjusted maternal dose, which is well below the 10 percent threshold generally considered safe for breastfed infants. The National Institutes of Health LactMed database considers metformin compatible with breastfeeding for most women, though monitoring the infant for hypoglycemia is reasonable.

Humana covers metformin postpartum under the same formulary rules as at any other life stage. Postpartum women with gestational diabetes history who are now using metformin for prediabetes prevention should ensure their new postpartum diagnosis code is submitted, not the gestational code, to avoid claim confusion.

Perimenopause: The Underserved Coverage Scenario

Here is a life-stage scenario almost no insurance article addresses. Perimenopause, the 2 to 10 years before the final menstrual period, is associated with progressive insulin resistance driven by fluctuating and declining estrogen. A study published in Menopause found that insulin sensitivity decreases by approximately 30 percent across the menopausal transition, independent of weight gain. This is why many women in their 40s and early 50s who have never had metabolic issues suddenly develop prediabetes or find their blood sugar control worsening.

A clinician-developed framework for women in this window:

Step 1. Get a fasting glucose and hemoglobin A1c. If A1c is 5.7 to 6.4 percent, you have prediabetes by ADA criteria.

Step 2. Discuss metformin with your prescriber. The Diabetes Prevention Program (DPP) trial showed metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31 percent over approximately three years in the full study population.

Step 3. Ensure the prescription is written with ICD-10 code R73.09 (prediabetes) or E11.x (type 2 diabetes) rather than a vague "metabolic disorder" code, because Humana's coverage for prediabetes prevention is more reliable under the prediabetes code.

Step 4. Request the $0 preventive coverage if your commercial Humana plan follows USPSTF guidelines on diabetes prevention pharmacotherapy.

Post-Menopause and Longevity Use

Metformin has attracted significant research interest as a potential longevity agent, driven in part by the TAME (Targeting Aging with Metformin) trial, a multi-site NIH-funded study enrolling adults 65 to 79 to determine whether metformin delays age-related disease. The trial is ongoing, and results are not yet published as of early 2025.

For post-menopausal women, metformin is currently covered by Humana when a qualifying diagnosis is present. Coverage for longevity or anti-aging indications without an associated metabolic diagnosis is not guaranteed, and prescribers writing metformin for this purpose off-label typically use a prediabetes or insulin-resistance code to ensure coverage. Whether that approach is appropriate depends on the individual clinical picture, not the insurance question alone.

Sex-Specific Pharmacology: How Metformin Works Differently in Women

Most patients ask about coverage, not pharmacokinetics, but understanding the sex-specific biology helps you understand why dose and monitoring matter.

GI Side Effects Are More Common in Women

Nausea, diarrhea, and abdominal discomfort occur at higher rates in women than in men starting metformin, likely because of slower gastric emptying on average and differences in GI motility. Starting at 500 mg once daily with food and titrating up by 500 mg per week substantially reduces this. Extended-release formulations improve tolerability. If your prescriber starts you on ER for this reason, the prior authorization process with Humana is straightforward.

Vitamin B12 Depletion

Long-term metformin use reduces B12 absorption in the terminal ileum. A 2010 analysis of the DPP Outcomes Study found that metformin users had a 13 percent lower B12 level than placebo users after nearly 5 years. Women are already at elevated risk of B12 deficiency during pregnancy, postpartum, and with vegan or vegetarian diets. Annual B12 monitoring is reasonable for any woman on long-term metformin, especially in the perimenopausal and post-menopausal years when neurological symptoms from deficiency can be mistaken for cognitive changes.

Renal Function and Dosing

Metformin is renally cleared. FDA labeling contraindicates metformin when eGFR falls below 30 mL/min/1.73 m² and recommends reassessing risk at eGFR 30 to 45. Women with autoimmune conditions, lupus nephritis, or recurrent UTIs that progress to pyelonephritis may have fluctuating eGFR; annual renal function checks matter in this group.

Evidence Gap: What We Don't Know in Women Specifically

Women have been underrepresented in foundational metformin trials. The DPP trial did include a large female cohort (68 percent women), making it one of the better-powered datasets for women. In the DPP, metformin's effect on diabetes prevention was particularly strong in women aged 25 to 44 with a history of gestational diabetes, with a 50 percent risk reduction in that subgroup.

However, the TAME longevity trial and most of the epidemiologic data on metformin and cardiovascular risk have not been specifically powered to detect sex differences in outcome. The breast cancer and endometrial cancer observational data suggesting metformin may reduce risk in obese women with insulin resistance are hypothesis-generating, not definitive. The evidence for metformin in female PCOS patients comes largely from trials with <100 participants and short follow-up, which limits confidence in long-term outcomes.

When a provider recommends metformin for you in a context other than type 2 diabetes or prediabetes, ask specifically: "Is there trial data in women like me, or is this extrapolated from a broader population?" That question will get you a better conversation than the insurance approval alone.

What to Do If Humana Denies Your Metformin Claim

Denials for metformin are uncommon but they happen, usually for one of three reasons: the diagnosis code does not match a covered indication, the ER formulation requires prior authorization, or there is a data entry error at the pharmacy.

Step-by-Step Appeal Process

1. Ask the pharmacist for the rejection code. Code 70 typically means non-covered drug; code 75 means prior authorization required.
2. Call the Humana pharmacy benefits line. Ask what documentation is needed to approve the claim.
3. Have your prescriber submit a prior authorization with the clinical rationale: type 2 diabetes, prediabetes (A1c value), PCOS with insulin resistance, or GI intolerance of IR metformin.
4. If the PA is denied, file a formal appeal within 60 days. Include the ADA Standards of Medical Care in Diabetes, which lists metformin as a first-line agent, as supporting clinical evidence.
5. If the appeal fails, request an external review through your state insurance commissioner. External reviewers overturn internal denials for standard-of-care drugs at meaningful rates.

Backup Affordability Options While You Appeal

Generic metformin IR costs approximately $4 to $10 for a 90-day supply at GoodRx pricing at major retail pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists metformin 500 mg at under $5 for 90 tablets. These are cash-pay options, not insurance, but they ensure you are not going without the drug during an appeal.

Who Is a Good Candidate for Metformin: Life-Stage and Condition Guide

This section is designed to give you a fast clinical picture of whether metformin makes sense to discuss with your prescriber, not to replace that conversation.

Good candidate scenarios for women:

• Type 2 diabetes at any age, any life stage, with adequate renal function
• Prediabetes (A1c 5.7 to 6.4 percent or fasting glucose 100 to 125 mg/dL), particularly if BMI >25 or if you have a gestational diabetes history
• PCOS with insulin resistance, anovulation, or metabolic features, regardless of diabetes status
• Perimenopausal women with new-onset insulin resistance and prediabetes confirmed on labs
• Gestational diabetes in women who cannot tolerate or decline insulin (with obstetric guidance)

Situations requiring caution or a different approach:

• eGFR <30 mL/min/1.73 m² (contraindicated)
• Active or heavy alcohol use (lactic acidosis risk)
• Planned contrast dye procedure (hold metformin 48 hours before and after per ACR guidance)
• Women with B12 deficiency already present (supplement before adding metformin)
• First trimester of pregnancy when the prescriber and patient agree to pause pending risk discussion